<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317002</url>
  </required_header>
  <id_info>
    <org_study_id>D7550C00003</org_study_id>
    <nct_id>NCT03317002</nct_id>
  </id_info>
  <brief_title>AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).</brief_title>
  <acronym>FLAVOUR</acronym>
  <official_title>A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in&#xD;
      patients with CAD. The study will be conducted at approximately 10 centres in 3 countries.&#xD;
      Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration&#xD;
      12 weeks).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in&#xD;
      patients with CAD. The study will be conducted at approximately 10 centres in 3 countries&#xD;
      (Denmark, Finland and Sweden).&#xD;
&#xD;
      Patients suitable for the study will be identified and screened for eligibility after being&#xD;
      hospitalized for Acute Coronary Syndrome (ACS) (Visit 1) comprising ST Elevation Myocardial&#xD;
      Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (non-STEMI). At Visit 1, after&#xD;
      signing informed consent, study measurements will take place at days 1, 2, 3 and 5 post ACS,&#xD;
      where feasible. It is planned that approximately 138 CAD patients will be randomized to&#xD;
      ensure at least 66 evaluable patients receiving AZD5718 Dose B or placebo are included with&#xD;
      12 weeks treatment. For supporting dose selection in future studies, a treatment arm with 28&#xD;
      randomized patients receiving AZD5718 Dose A is included in the study. The study was&#xD;
      originally designed to be a 4-week study and was amended to be a 12-week study. Therefore,&#xD;
      the total number of patients is greater than required for a 12 weeks study (about 100), since&#xD;
      some patients will only have 4 weeks of treatment.&#xD;
&#xD;
      An evaluable patient is defined as a patient with a valid Coronary Flow Velocity Reserve&#xD;
      (CFVR) measurement at Visit 2 and one post baseline visit as judged by the CFVR Core lab.&#xD;
&#xD;
      On Day 1 (Visit 2), 7 to 28 days after the ACS event, patients willing to participate in the&#xD;
      study will complete the screening procedure and, if eligible, be randomized. Treatment&#xD;
      duration will be 12 weeks. During the treatment phase, patients will come in to the clinic&#xD;
      for study measurements at 2 weeks (visit 3), 4 weeks (visit 4), 8 weeks (visit 4b) and 12&#xD;
      weeks (visit 4c).&#xD;
&#xD;
      A follow-up visit (Visit 5) will be performed at 4 weeks (±4 days) after last dose in order&#xD;
      to ensure safety and well-being of the patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">April 8, 2020</completion_date>
  <primary_completion_date type="Actual">April 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Creatinine-normalized u-LTE4 at Week 4</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine-normalized u-LTE4 at Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CFVR at Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CFVR at Week 4</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Plasma Concentrations of AZD5718</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LAD Hypereamic Flow at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>LAD=Left Anterior Descending</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LVEF at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>LVEF=Left Ventricular Ejection Fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>LV=Left Ventricular</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LV-GLS at Rest at Week 4</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>LV-GLS = Left Ventricular Global Longitudinal Strain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LV-GCS at Rest at Week 4</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>LV-GCS = Left Ventricular Global Circumferential Strain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>LAD=Left Anterior Descending</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>AZD5718 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5718 Dose A once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5718 Dose B once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5718</intervention_name>
    <description>Oral dose of AZD5718 (tablet)</description>
    <arm_group_label>AZD5718 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5718</intervention_name>
    <description>Oral dose of AZD5718 (tablet)</description>
    <arm_group_label>AZD5718 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (tablet)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females of non-childbearing potential&#xD;
&#xD;
          -  Age ≥18 to ≤75&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥18 to ≤35 kg/m2&#xD;
&#xD;
          -  CAD patients, here defined as:&#xD;
&#xD;
        ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event&#xD;
        documented by Electrocardiogram (ECG), cardiac enzymes [troponin] and angiogram) Provision&#xD;
        of signed and dated, written informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled Type 1 or Type 2 diabetes defined as haemoglobin A1c (HbA1c) Diabetes&#xD;
&#xD;
          -  Control and Complications Trial (DCCT)&gt; 9% or International Federation of Clinical&#xD;
             Chemistry (IFCC) &gt;74.9 mmol/mol&#xD;
&#xD;
          -  Patients with atrial fibrillation (chronic or current) or history of ventricular&#xD;
             tachycardia requiring therapy for termination, or symptomatic sustained ventricular&#xD;
             tachycardia or sick sinus syndrome or Atrioventricular blockage degree 2-3&#xD;
&#xD;
          -  Prior coronary artery by-pass graft (Coronary artery bypass grafting) to Left Anterior&#xD;
             Descending artery (LAD)&#xD;
&#xD;
          -  Left ventricle ejection fraction &lt; 30%&#xD;
&#xD;
          -  Unacceptable level of angina despite maximal medical therapy or unstable angina at&#xD;
             entry&#xD;
&#xD;
          -  Canadian Cardiovascular Society (CCS) ≥ 3 (Visit 1 or Visit 2)&#xD;
&#xD;
          -  Stroke within the previous 6 months from ACS or ongoing treatment with Persantin or&#xD;
             Asasantin&#xD;
&#xD;
          -  Chronic use of anticoagulants on therapeutic dose (not including thrombosis&#xD;
             prophylaxis) during the study&#xD;
&#xD;
          -  Planned additional cardiac intervention (e.g., Percutaneous coronary intervention&#xD;
             (PCI), Coronary artery bypass grafting (CABG) within next 6 months&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III-IV heart failure or decompensated heart&#xD;
             failure at discharge or hospitalization for exacerbation of chronic heart failure&#xD;
             within the previous 3 months from ACS&#xD;
&#xD;
          -  Previously known severe renal disease (Chronic Kidney Disease (CKD) stage 4 or 5) or&#xD;
             previously known creatinine clearance calculated by Cockcroft Gault equation &lt;30&#xD;
             ml/min*m2&#xD;
&#xD;
          -  Known allergy to adenosine and mannitol, or experience of previous adverse effects of&#xD;
             adenosine stress testing.&#xD;
&#xD;
          -  Participation in another interventional clinical study with an investigational&#xD;
             pharmaceutical product during the last 3 months also including drug eluting stents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <zip>222 42</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D7550C00003&amp;amp;attachmentIdentifier=bfc8ef9d-0ec7-4ad9-9153-27fb6e2d880e&amp;amp;fileName=Statistical_Analysis_Plan_redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>redacted Statistical Analysis Plan</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D7550C00003&amp;amp;attachmentIdentifier=72c1cf18-0bad-4d45-a0cd-640350986d43&amp;amp;fileName=Clinical_Study_Protocol_redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>redacted Clinical Study Protocol</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03317002/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03317002/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in 3 countries at 9 sites; 3 in Denmark, 2 in Finland and 4 in Sweden.</recruitment_details>
      <pre_assignment_details>Participants underwent a screening visit between 2 and within 27 days before receiving the first dose of IP.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD5718 (200 mg)</title>
          <description>AZD5718 (200 mg)</description>
        </group>
        <group group_id="P2">
          <title>AZD5718 (50 mg)</title>
          <description>AZD5718 (50 mg)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD5718 (200 mg)</title>
          <description>AZD5718 (200 mg)</description>
        </group>
        <group group_id="B2">
          <title>AZD5718 (50 mg)</title>
          <description>AZD5718 (50 mg)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="8.21"/>
                    <measurement group_id="B2" value="61.4" spread="8.12"/>
                    <measurement group_id="B3" value="61.1" spread="8.51"/>
                    <measurement group_id="B4" value="61.5" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Creatinine-normalized u-LTE4 at Week 4</title>
        <description>Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine-normalized u-LTE4 at Week 4</title>
          <description>Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="92.55"/>
                    <measurement group_id="O2" value="0.09" spread="84.32"/>
                    <measurement group_id="O3" value="1.09" spread="44.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine-normalized u-LTE4 at Week 12</title>
        <description>Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine-normalized u-LTE4 at Week 12</title>
          <description>Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="92.55"/>
                    <measurement group_id="O2" value="0.09" spread="84.32"/>
                    <measurement group_id="O3" value="1.09" spread="44.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Ratio</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CFVR at Week 12</title>
        <description>CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CFVR at Week 12</title>
          <description>CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="23.64"/>
                    <measurement group_id="O2" value="0.98" spread="39.53"/>
                    <measurement group_id="O3" value="1.16" spread="33.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CFVR at Week 4</title>
        <description>CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CFVR at Week 4</title>
          <description>CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="28.34"/>
                    <measurement group_id="O2" value="1.15" spread="31.47"/>
                    <measurement group_id="O3" value="1.08" spread="33.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Plasma Concentrations of AZD5718</title>
        <time_frame>16 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Plasma Concentrations of AZD5718</title>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: 1-8 Hours Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611.88" spread="234.50"/>
                    <measurement group_id="O2" value="47.88" spread="497.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks (Visit 3): 20-28 Hours Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.36" spread="90.97"/>
                    <measurement group_id="O2" value="16.57" spread="127.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (Visit 4): Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" spread="68.17"/>
                    <measurement group_id="O2" value="11.01" spread="60.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (Visit 4): 0-2 Hours Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.28" spread="243.04"/>
                    <measurement group_id="O2" value="38.68" spread="159.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (Visit 4): 2-4 Hours Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919.22" spread="51.26"/>
                    <measurement group_id="O2" value="148.64" spread="71.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks (Visit 4): 4-8 Hours Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649.09" spread="49.89"/>
                    <measurement group_id="O2" value="105.40" spread="52.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks (Visit 4c): Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.39" spread="91.52"/>
                    <measurement group_id="O2" value="13.97" spread="88.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks (Visit 5) - FUP 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="16.39"/>
                    <measurement group_id="O2" value="0.50" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LAD Hypereamic Flow at 4 Weeks</title>
        <description>LAD=Left Anterior Descending</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LAD Hypereamic Flow at 4 Weeks</title>
          <description>LAD=Left Anterior Descending</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.16"/>
                    <measurement group_id="O2" value="0.04" spread="0.16"/>
                    <measurement group_id="O3" value="0.03" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LVEF at 4 Weeks</title>
        <description>LVEF=Left Ventricular Ejection Fraction</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LVEF at 4 Weeks</title>
          <description>LVEF=Left Ventricular Ejection Fraction</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>percent LVEF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="5.30"/>
                    <measurement group_id="O2" value="2.70" spread="6.39"/>
                    <measurement group_id="O3" value="0.48" spread="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks</title>
        <description>LV=Left Ventricular</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks</title>
          <description>LV=Left Ventricular</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>1/s</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="30.61"/>
                    <measurement group_id="O2" value="0.98" spread="33.55"/>
                    <measurement group_id="O3" value="1.03" spread="30.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LV-GLS at Rest at Week 4</title>
        <description>LV-GLS = Left Ventricular Global Longitudinal Strain</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV-GLS at Rest at Week 4</title>
          <description>LV-GLS = Left Ventricular Global Longitudinal Strain</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>Percent LV-GLS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="3.00"/>
                    <measurement group_id="O2" value="0.34" spread="2.47"/>
                    <measurement group_id="O3" value="-0.63" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LV-GCS at Rest at Week 4</title>
        <description>LV-GCS = Left Ventricular Global Circumferential Strain</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV-GCS at Rest at Week 4</title>
          <description>LV-GCS = Left Ventricular Global Circumferential Strain</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="7.24"/>
                    <measurement group_id="O2" value="1.71" spread="5.40"/>
                    <measurement group_id="O3" value="-1.88" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks</title>
        <description>LAD=Left Anterior Descending</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Number of participants analysed differs from participant flow module due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>AZD5718 (200 mg)</title>
            <description>AZD5718 (200 mg)</description>
          </group>
          <group group_id="O2">
            <title>AZD5718 (50 mg)</title>
            <description>AZD5718 (50 mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks</title>
          <description>LAD=Left Anterior Descending</description>
          <population>Number of participants analysed differs from participant flow module due to missing data</population>
          <units>m/sec</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="23.31"/>
                    <measurement group_id="O2" value="0.92" spread="23.68"/>
                    <measurement group_id="O3" value="0.99" spread="20.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment period, up to 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD5718 (200 mg)</title>
          <description>AZD5718 (200 mg)</description>
        </group>
        <group group_id="E2">
          <title>AZD5718 (50 mg)</title>
          <description>AZD5718 (50 mg)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.03</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

